观察蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效差异。回顾性分析2012年1月至2018年12月就诊于我院的405例单侧原发性乳腺癌女性患者的临床资料,按新辅助化疗所应用的方案划分为蒽环类、紫杉类联合组(299例)及蒽环类、紫杉类序贯组(106例)。入组患者都经过至少4个周期的新辅助化疗(neoadjuvant chemotherapy, NAC)。对两组方案的客观缓解率(objective response rate, ORR)和病理完全缓解率(pathologic complete response, pCR)进行比较,并比较不同分子亚型对ORR及pCR的影响。蒽环类、紫杉类联合方案与蒽环类、紫杉类序贯方案的ORR无统计学差异(P = 0.333 > 0.05),pCR无统计学差异(P = 0.650 > 0.05)。Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的ORR无统计学差异(P = 0.762 > 0.05)、pCR具有统计学差异(P = 0.003 < 0.05)。蒽环类和紫杉类联合方案与序贯方案疗效相仿,三阴型及Her-2过表达型乳腺癌较Luminal型乳腺癌对新辅助化疗的疗效更佳。
To study the efficacy of anthracycline combined with taxane and sequential regimen in neoadjuvant chemotherapy of breast cancer, the clinical data of 405 female patients with unilateral primary breast cancer who received treatment in our hospital from January 2012 to December 2018 were analyzed retrospectively. According to the regimens used in neoadjuvant chemotherapy, they were divided into anthracycline combined with taxane group (299 cases) and anthracycline sequential taxane group (106 cases). All patients underwent neoadjuvant chemotherapy (NAC) for at least four cycles. Objective response rate (ORR) and pathologic complete response (pCR) were compared between the two groups, and the effects of different molecular subtypes on ORR and pCR were compared. There was no significant difference in ORR (P = 0.333 > 0.05) and pCR (P = 0.650 > 0.05) between anthracycline combined with taxane regimen and anthracycline sequential taxane regimen; There was no significant difference in ORR (P = 0.762 > 0.05) and significant difference in PCR (P = 0.003 < 0.05) among Luminal A, Luminal B, Her-2 over-expression and triple-negative breast cancers. The efficacy of anthracycline combined with taxane regimen is similar to that of sequential regimen. The efficacy of neoadjuvant chemotherapy in triple-negative and HER-2 over-expression breast cancers is better than that in Luminal breast cancers.
乳腺癌,新辅助化疗,蒽环类,紫杉类, Breast Cancer Neoadjuvant Chemotherapy Anthracycline Taxane摘要
To study the efficacy of anthracycline combined with taxane and sequential regimen in neoadjuvant chemotherapy of breast cancer, the clinical data of 405 female patients with unilateral primary breast cancer who received treatment in our hospital from January 2012 to December 2018 were analyzed retrospectively. According to the regimens used in neoadjuvant chemotherapy, they were divided into anthracycline combined with taxane group (299 cases) and anthracycline sequential taxane group (106 cases). All patients underwent neoadjuvant chemotherapy (NAC) for at least four cycles. Objective response rate (ORR) and pathologic complete response (pCR) were compared between the two groups, and the effects of different molecular subtypes on ORR and pCR were compared. There was no significant difference in ORR (P = 0.333 > 0.05) and pCR (P = 0.650 > 0.05) between anthracycline combined with taxane regimen and anthracycline sequential taxane regimen; There was no significant difference in ORR (P = 0.762 > 0.05) and significant difference in PCR (P = 0.003 < 0.05) among Luminal A, Luminal B, Her-2 over-expression and triple-negative breast cancers. The efficacy of anthracycline combined with taxane regimen is similar to that of sequential regimen. The efficacy of neoadjuvant chemotherapy in triple-negative and HER-2 over-expression breast cancers is better than that in Luminal breast cancers.
吴 茜,孔德志,何 林,宋玉华. 蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效观察Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer[J]. 临床医学进展, 2020, 10(09): 1874-1882. https://doi.org/10.12677/ACM.2020.109282
参考文献ReferencesGu, X., Zhang, Y., Chen, L., Guo, J. and Zhang, W.H. (2015) Efficacy of Neo-Adjuvant Chemotherapy with TEC Regimen on Breast Cancer. Cancer Chemotherapy and Pharmacology, 75, 301-308.
<br>https://doi.org/10.1007/s00280-014-2646-yUS Preventive Services Task Force (2019) Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 322, 857-867. <br>https://doi.org/10.1001/jama.2019.11885Asiri, S., Asiri, A., Ulahannan, S., Alanazi, M., Humran, A. and Hummad, A. (2020) Incidence Rates of Breast Cancer by Age and Tumor Characteristics among Saudi Women: Recent Trends. Cureus, 12, e6664.
<br>https://doi.org/10.7759/cureus.6664Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30.
<br>https://doi.org/10.3322/caac.21387Chien, A.J., Tripathy, D., Albain, K.S., et al. (2020) MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology, 38, 1059-1069.
<br>https://doi.org/10.1200/JCO.19.01027Rastogi, P., Anderson, S.J., Bear, H.D., et al. (2008) Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology, 26, 778-785.
<br>https://doi.org/10.1200/JCO.2007.15.0235Chen, X.S., Ye, G.L., Zhang, C., et al. (2013) Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide versus Docetaxel plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer. Breast Cancer Research and Treatment, 142, 549-558.
<br>https://doi.org/10.1007/s10549-013-2761-1Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S. and Cardoso, F. (2015) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 26, V8-V30. <br>https://doi.org/10.1093/annonc/mdv298Wolff, A.C., Hammond, M.E., Hicks, D.G., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013. <br>https://doi.org/10.1200/JCO.2013.50.9984Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
<br>https://doi.org/10.1016/j.breast.2014.06.004Untch, M., Konecny, G.E., Paepke, S. and Von Minckwitz, G. (2014) Current and Future Role of Neoadjuvant Therapy for Breast Cancer. The Breast, 23, 526-537. <br>https://doi.org/10.1016/j.breast.2014.06.004Bear, H.D., Anderson, S., Smith, R.E., et al. (2006) Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 24, 2019-2027. <br>https://doi.org/10.1200/JCO.2005.04.1665Von Minckwitz, G., Untch, M., Nüesch, E., et al. (2011) Impact of Treatment Characteristics on Response of Different Breast Cancer Phenotypes: Pooled Analysis of the German Neo-Adjuvant Chemotherapy Trials. Breast Cancer Research and Treatment, 125, 145-156. <br>https://doi.org/10.1007/s10549-010-1228-xHerrada, J., Iyer, R.B., Atkinson, E.N., et al. (1997) Relative Value of Physical Examination, Mammography, and Breast Sonography in Evaluating the Size of the Primary Tumor and Regional Lymph Node Metastases in Women Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Carcinoma. Clinical Cancer Research, 3, 1565-1569.Chen, W.C., He, J.S., Song, S.F., Wang, M., Wu, H.S. and Wang, X.M. (2015) Efficacy of TCH/TEC Neoadjuvant Chemotherapy for the Treatment of HER-2-Overexpressing Breast Cancer. Oncology Letters, 9, 1922-1926.
<br>https://doi.org/10.3892/ol.2015.2912Von Minckwitz, G., Untch, M., Blohmer, J.U., et al. (2012) Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 30, 1796-1804. <br>https://doi.org/10.1200/JCO.2011.38.8595Vila, J., Teshome, M., Tucker, S.L., Woodward, W.A., Chavez-MacGregor, M., Hunt, K.K. and Mittendorf, E.A. (2017) Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-Regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 265, 574-580.
<br>https://doi.org/10.1097/SLA.0000000000001492胡赛男, 俞乔, 胡亦钦, 等. EC序贯P剂量密集方案与TEC方案在乳腺癌新辅助化疗中的疗效比较[J]. 临床肿瘤学杂志, 2015, 20(4): 327-332.凌丰军. EC序贯P剂量密集方案与TEC方案在乳腺癌新辅助化疗中的疗效分析[J]. 国际医药卫生导报, 2016, 22(19): 2995-2998.Gogia, A., Raina, V., Deo, S.V., et al. (2014) Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: Institutional Experience. Asian Pacific Journal of Cancer Prevention, 15, 1989-1992.
<br>https://doi.org/10.7314/APJCP.2014.15.5.1989Liu, Y., Xu, Z.G., Zhang, Z.Y., Wen, G.F., Sun, J.X. and Han, F. (2018) Efficacy and Safety of TE/TEC/Intensive Paclitaxel Neoadjuvant Chemotherapy for the Treatment of Breast Cancer. Oncology Letters, 17, 907-912.
<br>https://doi.org/10.3892/ol.2018.9658Houssami, N., Macaskill, P., Von Minckwitz, G., Marinovich, M.L. and Mamounas, E. (2012) Meta-Analysis of the Association of Breast Cancer Subtype and Pathologic Complete Response to Neoadjuvant Chemotherapy. European Journal of Cancer, 48, 3342-3354. <br>https://doi.org/10.1016/j.ejca.2012.05.023Díaz-Casas, S.E., Castilla-Tarra, J.A., Pena-Torres, E., et al. (2019) Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. The Oncologist, 24, e1360-e1370. <br>https://doi.org/10.1634/theoncologist.2019-0300Stamatovic L, Susnjar S, Gavrilovic D, et al. (2018) The Influence of Breast Cancer Subtypes on the Response to Anthracycline Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. Journal of BUON, 23, 1273-1280.Subbiah, S., Gopu, G., Senthilkumar, P. and Muniasamy, P (2017) Molecular Subtypes as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Indian Journal of Cancer, 54, 652-657.
<br>https://doi.org/10.4103/ijc.IJC_238_17Lindström, L.S., Karlsson, E., Wilking, U.M., et al. (2012) Clinically Used Breast Cancer Markers Such as Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable throughout Tumor Progression. Journal of Clinical Oncology, 30, 2601-2608. <br>https://doi.org/10.1200/JCO.2011.37.2482